– IRELAND, Dublin – Venn Life Sciences (AIM: VENN), a growing Clinical Research Organisation providing clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, announces the appointment of Allan Wood as Chairman to the Board with effect from 20 September 2016 taking over from Tony Richardson who has been acting as Executive Chairman since January 2016.
Allan Leigh Wood, aged 52, was previously Managing Director of Xansa Plc, an outsourcer of business processing solutions. Since then he has held a number of positions as a Non-Executive Director and Chairman of multiple companies across a broad range of fields where he has acquired skills that will benefit Venn.
Tony Richardson, Chief Executive Officer of Venn said:”I am delighted to welcome Allan to Venn. Allan has extensive relevant experience in scaling businesses in health services and related sectors and I believe will add significant value as we seek to continue our current growth trajectory. Allan’s experience includes both organic business growth and M&A and together we can continue to build a successful and sustainable business for shareholders.”
About Venn Life Sciences
Venn Life Sciences is a Contract Research Organisation providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations. With dedicated operations in France, Germany, the Netherlands, the UK, Ireland and Europe wide representation – Venn specialises in rapid deployment and management of multisite projects. Venn also has an innovation division – Innovenn – focused primarily on breakthrough development opportunities in Skin Science.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.